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Abstract  
Following the landmark approvals by the United States Food and Drug Administration, the 
adoptive transfer of CD19-directed chimeric antigen receptor (CAR) T-cells has now entered 
mainstream clinical practice for patients with chemotherapy-resistant or refractory B-cell 
malignancies. These approvals have followed on from a prolonged period of pre-clinical 
evaluation, informing the design of clinical trials that have demonstrated unprecedented 
efficacy in this difficult to treat patient population. However, the delivery of autologous 
CAR-engineered T-cell therapy is complex, costly and not without significant risk. Here we 
summarize the key themes of CAR T-cell preclinical development and highlight a number of 
innovative strategies designed to further address toxicity and improve efficacy. In concert 
with the emerging promise of precision genome editing, it is hoped these next generation 
products will increase the repertoire of clinical applications of CAR T-cell therapy in 
malignant and perhaps other disease settings.  
 
 
Key words  
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Introduction 
Chimeric Antigen Receptor (CAR) T-cell immunotherapy has shown substantial anti-
tumor activity against refractory B-cell malignancy [1]. Indeed, therapeutic efficacy is 
unprecedented for a new cancer medicine with response rates of up to 90% for patients with 
relapsed/ refractory B-cell acute lymphoblastic leukemia (B-ALL) and over 60% for patients 
with non-Hodgkin’s lymphoma (NHL) [2]. Immunotherapy using CAR T-cells is generally 
undertaken following the administration of lymphodepleting chemotherapy. This intervention 
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increases access to supportive cytokines (e.g. IL-7 and IL-15) [3], creates a viable spatial 
compartment for CAR T-cell growth and persistence [4] and depletes systemic and tumor-
resident CD4+ CD25+ regulatory T-cells (Tregs) [5]. Nevertheless, toxicity of CAR T-cell 
immunotherapy administered in the context of prior lymphodepletion can be life threatening, 
a factor that requires careful consideration during pre-clinical development. 
 
Structure of Chimeric Antigen Receptors 
Chimeric antigen receptors are engineered proteins that contain an antigen recognition 
domain - most commonly a single chain variable fragment (scFv) - linked via a hinge or 
spacer and transmembrane domain to a bespoke signaling domain [6] (Figure 1). In initial 
configurations, a T-cell receptor (TCR)-like signal 1 alone was provided, generally using a 
module that contains one or more immunoreceptor tyrosine-based activation motifs (ITAM), 
such as CD3ζ. However, immunotherapy using T-cells that were engineered to express these 
“first generation” CARs proved ineffective, largely owing to inadequate T-cell persistence 
and expansion in vivo [7]. Second and third generation CARs respectively incorporate one or 
two intracellular co-stimulatory domains such as CD28, CD137 (4-1BB), OX40 or ICOS, 
thereby providing signal 2 for T-cell activation [7]. This development translated into 
improved CAR efficacy and functionality, although it remains doubtful as to whether third 
generation CARs are truly superior to their second generation counterparts. More recently, a 
range of fourth generation CARs have been described in which additional signals are 
delivered to enhance potency (e.g. inducible release of interleukin (IL)-12). Since CAR T-
cells bind in an antibody-like manner, targeting is independent of human leukocyte antigen 
(HLA) haplotype or tumor-associated HLA downregulation. Furthermore, engagement of 
non-protein antigens such as carbohydrates and gangliosides can be achieved.   
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Selection of scFv for CAR T-cell targeting 
Target selection is crucial in the design of CARs to achieve optimal safety and 
efficacy [8]. Success of CAR T-cell immunotherapy of B-cell malignancy reflects the 
widespread expression of CD19 on the transformed cell population, but not on hematopoietic 
stem cells or terminally differentiated plasma cells. Building on this, CARs targeting other B-
cell antigens (e.g. CD20 and CD22) for the treatment of leukaemia and lymphomas have been 
developed. This is especially important as loss of CD19 expression has been reported in 
relapsed patients and CD19 negative populations have been found in malignancies.  
Almost all anti-CD19 CARs currently undergoing clinical evaluation contain murine 
scFvs. While durable remissions have been achieved, CD19+ disease relapse may also ensue, 
accompanied by the loss of circulating CAR T-cells [9]. While this may be influenced by 
choice of co-stimulatory domain [10] and tonic signaling [11], T-cell responses against 
epitopes derived from murine scFvs may occur. This highlights the desirability of selection of 
humanized and fully human scFvs, as recently evaluated in patients with advanced NHL [12]. 
A novel approach to enhance target antigen repertoire involves the re-direction CAR 
specificity against HLA-restricted peptide antigens that are derived from intracellular tumor 
antigens, such as Wilms Tumour (WT)1. Use of scFvs that bind specifically to individual 
HLA/peptide complexes significantly expands the range of potential CAR targets and holds 
great potential to expand the successful and safe delivery of CAR T-cell immunotherapy [13].  
 
Selection of hinge/spacer and transmembrane elements 
Selection of hinge or transmembrane region can also influence activity of CAR T-cell 
immunotherapy. Illustrating this, second generation CD19-specific CAR T-cells that contain 
a CD28 hinge and transmembrane domain elicited greater target-dependent cytokine release  
and activation-induced cell death compared to CAR T-cells in which these elements 
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originated from CD8α [14]. While in vivo potency was similar, use of a CD8α hinge and 
transmembrane region may cause reduced cytokine release and limit toxicity in patients [14].  
 
Costimulatory domains 
Clinically evaluated second generation CARs utilize either a CD28 or 4-1BB 
costimulatory module and both have shown impressive outcomes [9, 15]. Initial pre-clinical 
comparisons of anti-CD19 CD28ζ and 4-1BBζ CARs demonstrated comparable anti-tumor 
activity, although cytokine release appears to be slower and of lower magnitude with 4-1BBζ 
CARs [16, 17]. Many pre-clinical studies have employed high T-cell doses, leading to 
complete tumor eradication, meaning that subtle differences may remain undetected. By 
lowering T-cell doses, Zhao et al. demonstrated that anti-CD19 4-1BBζ CAR T-cells mediate 
slower tumor elimination than CD28ζ, but have greater persistence, thus resulting in similar 
overall therapeutic benefit [18].  
 
Vector delivery systems 
Most commonly, CAR-encoding genes are delivered to T-cells using γ-retroviral or 
lentiviral vectors [6]. Concerns regarding the potential risk of insertional mutagenesis have 
not been realized in practice as yet [19]. Alternative strategies include mRNA [20] or 
transposon/transposase plasmid electroporation [21]. Vector and promoter selection may have 
several consequences with regard to CAR T-cell efficacy and persistence. Retrovirally-
transduced CARs may be subject to transcriptional repression, particularly during periods of 
quiescence. To mitigate this, Thomas et al. have shown that the insertion of a human β-
interferon scaffold attachment region (SAR) into a γ-retroviral vector promoted sustained 
CAR transgene expression, when compared to non-SAR containing controls [22]. Ligand-
independent CAR tonic signaling has been identified in a number of disparate settings 
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(typically using scFv-containing CARs) [23-26] and may arise as a consequence of high CAR 
surface expression. The latter is influenced in part by promoter strength and the type of vector 
used. Gomes-Silva et al. recently reported that 4-1BB-mediated ligand-independent tonic 
signaling may lead to enhanced apoptosis and poor ex vivo expansion due to a self-
amplifying NF-κB positive feedback loop, acting at the level of the γ-retroviral long terminal 
repeat (LTR) promoter [25]. These issues may be addressed by using self-inactivating (SIN) 
or non-integrating lentiviral vectors (NILVs) [27]. More recently, CARs have been 
introduced by precise gene editing using CRISPR/Cas9 [28] or engineered homing 
endonucleases [29]. Placement of the CAR gene within the TCR α constant (TRAC) locus 
has been shown to recapitulate endogenous TCR expression and recycling, thereby 
alleviating the deleterious effects of tonic signaling upon terminal differentiation, exhaustion 
and anti-tumor activity [28]. This approach also lends itself to the production of allogeneic 
“off the shelf” CAR T-cells by simultaneously knocking out functional TCR, thus 
minimizing the risk of graft versus host disease [30]. 
 
Next generation CARs 
Considerable progress has been made in further engineering CAR T-cells to optimize 
in vivo performance and safety [31]. Various strategies have been deployed to enhance 
intrinsic CAR function [32]; lower the threshold for activation [33]; aid trafficking and intra-
tumoral migration [34, 35]; engender CAR temporo-spatial control [36, 37] and to enable the 
pharmacologically regulated elimination of these cells in the event of excessive toxicity [38]. 
To limit antigen escape and/or facilitate pattern recognition on tumor cells, CARs have been 
designed with dissociated endodomains placed in trans [39, 40], dual targeting domains 
(tandem CARs) [41] or logic circuits [42]. To enhance fitness of CAR T-cells, efforts have 
been made to optimize their differentiation [43] and metabolic capacity [44]. Alternatively, 
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potency of tumor attack may be enhanced by recruitment/ induction of innate and adaptive 
anti-tumor immune responses [45, 46]; resistance to intrinsic [34, 47, 48] or induced [49] 
immunosuppression in the tumor microenvironment (TME). Chimeric antigen receptors have 
also been designed to function in a more modular and customisable fashion [50] in 
anticipation of available “off the shelf” cellular therapeutics [51]. An overview of these 
approaches is summarized in Figure 2 while individual strategies are described in the sections 
that follow. 
 
Dual antigen targeting 
The emergence of acquired resistance to CAR T-cell immunotherapy through antigen 
loss [52] or lineage plasticity [53] had been predicted using several preclinical models. 
Immunotherapy of patients with B-cell malignancy has resulted in CD19- clonal escape, 
mediated at least in part by alternative exon splicing [54]. In a mouse model of CAR-
mediated antigen loss, dual expression of CARs targeting CD19 and CD123 led to superior 
activity against human B-ALL compared to single targeted CAR T-cells or the pooled 
combination of CD19 and CD123-directed T-cells. Likewise, the design of tandem CARs 
containing two or more extracellular binding moieties (e.g. targeting CD19 and CD20 [55] or 
CD19 and CD22 [56]) may recapitulate the advantages of using multiple CARs in a single 
CAR molecule. 
 
Logic-gated CARs 
The paucity of unique tumor-specific cell surface antigens means that substantial 
concerns remain regarding risk of on-target off-tumor toxicity. Logic-gated CARs utilizing 
Boolean operations such as AND, OR and NOT have been designed to enhance specificity 
and potentially reduce off-target effects [57]. Their development provides the rudimentary 
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tools for generating programmable CAR T-cells capable of sophisticated pattern recognition. 
OR gates may be enforced by using multiple CARs in trans or a single tandem CARs. Thus 
far, NOT gates have typically relied upon co-expressed inhibitory CARs (termed iCARs) 
containing an immune checkpoint-derived endodomain (e.g. from PD-1) [58]. However, 
differences in antigen density and/or the strength of positive and negative signaling may 
interfere with the function of iCARs in vivo. Designing an efficacious AND gate is somewhat 
more complex but various strategies have been described. Cordoba et al. have developed a 
strategy whereby an antigen targeting moiety is bound to a CD45 or CD148 phosphatase-
derived transmembrane and endodomain [59]. These phosphatases typically play a role in 
regulating TCR-mediated cytolytic function and, owing to the large size of their ectodomain, 
they are sterically excluded from the immune synapse (as predicted by the kinetic segregation 
model) [60]. By contrast, unbound chimeric CD45 or CD148 may negatively regulate 
activation of a second CAR in a tonic fashion. Binding of target antigen sequesters the 
chimeric phosphatase, abrogating tonic CAR ITAM dephosphorylation and allowing the 
latter to induce T-cell activation following the binding of a second cognate ligand.  
In an alternative strategy, Roybal et al. have designed a customizable logic-gated gene 
circuit system termed synNotch. To create synNotch, an extracellular targeting moiety is 
fused to a cleavable transmembrane domain (derived from the Notch receptor’s core 
regulatory region) followed by an endodomain containing a synthetic transcription factor 
[42]. Upon target binding, the synNotch receptor is cleaved at the cell surface by 
metalloproteases and γ-secretase, releasing the synthetic transcription factor to induce 
orthogonal expression of a secondary CAR or iCAR. Potential limiting factors include the 
immunogenicity of using non-native or synthetic transcription factors, the relatively slow 
kinetics of the system due to its reliance on induced transcription and potential off-target 
effects due to synNotch CAR T-cells exiting the tumor following initial activation.  
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Another potential issue pertinent to AND-gated systems relates to selective antigen 
loss due to clonal evolution and tumor heterogeneity. Conceptually, this may be addressed by 
using multiple programmable CAR circuits that introduce fuzzy, conditional and/or non-
binary (i.e. analog) outcomes. Illustrating this, split CARs may be employed whereby CD3ζ 
and costimulatory domains are spatially separated in trans and bound to different targeting 
moieties [39]. 
 
Growth promoting and costimulatory receptors 
A plethora of additional endogenous or synthetic chimeric receptor types have been 
introduced into CAR T-cells to optimize function in a paracrine fashion. Examples include 
chimeric cytokine receptors comprising an IL-4Rα ectodomain and IL-2/15Rβ [61] or IL-7Rα 
[62] endodomain. Both mediate enhanced ex vivo expansion and enrichment of CAR T-cells 
following exposure to IL-4. Alternatively, enforced overexpression of IL7Rα may achieve 
IL-7-dependent increase in anti-tumor activity accompanied by Treg resistance [63]. 
Expression of CD40 ligand may be used to promote activation of professional antigen 
presenting cells [45]. A membrane-tethered chimeric IL-15/ IL-15 receptor α fusion molecule 
has been used to enhance T-cell persistence and memory stem-cell phenotype independent of 
CAR signaling [64]. Expression of 4-1BB ligand in CAR T-cells promotes enhanced 
juxtacrine activation of these T-cells and neighboring endogenous T-cells [18]. Finally, 
chimeric switch receptors may be employed that link the extracellular domain of an 
inhibitory immune checkpoint receptor with the intracellular signaling domain of a 
costimulatory receptor (e.g. PD-1/CD28 or PD-1/4-1BB) [65], thereby mitigating CAR T-cell 
exhaustion in the tumor microenvironment. 
 
TRUCKs and armored CARs 
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“Armored” CARs have been engineered to constitutively produce cytokines that favor CAR 
T-cell expansion and effector function, accompanied by resistance to negative influences of 
the TME such as Tregs. T-cells that have been engineered to co-express a CAR and a 
cytokine (e.g. IL-12) that is produced in an NFAT-inducible fashion following activation 
have been termed “TRUCKs” [66].  Similarly, CD19-directed CARs engineered to secrete 
single chain IL-12 could safely eradicate established disease despite the absence of prior 
lymphodepleting conditioning [67]. Such an approach may simultaneously induce a 
bystander effect by re-programming tumor-resident myeloid cells to cross-prime endogenous 
HLA-restricted tumor-infiltrating lymphocytes (TILs) [68] or by inducing macrophages to 
target cancer cells that have evolved to downregulate antigen presentation [69]. CD19-
specific CAR T-cells engineered to constitutively express the γc-cytokines IL-2, IL-7, IL-15 
or IL-21 all demonstrated enhanced anti-tumor efficacy in immune compromised mice, albeit 
to varying degrees and through singularly different mechanisms. Specifically, IL-7 and IL-
21-transduced T-cells demonstrated greatest efficacy in vivo, while IL-21 and IL-15 
promoted long-term CAR T-cell persistence, albeit with divergent effector memory and 
central memory phenotypes [70]. Separately, CD19-directed CAR T-cells have been 
engineered to constitutively express IL-15, improving antigen-driven expansion and efficacy 
while reducing exhaustion and apoptosis [71]. Indeed, local production of IL-15 was shown 
to elicit local CAR T-cell activation via activation of the phosphatidylinositol 3’-kinase/Akt 
pathway, resulting in upregulated expression of anti-apoptotic molecules such as Bcl-2 [72]. 
Contrasting with the “TRUCK” approach, Koneru et al. designed a MUC16-specific CAR in 
which the IL-12 gene was placed downstream of an internal ribosome entry site (IRES) 
element. This approach resulted in the production of lower levels of IL-12 compared to CARs 
expressing NFAT IL-12 and was found to cause less toxicity in mice [73] [74]. Based on the 
evidence of efficacy against human ovarian tumours in mouse models, this armored IL-12 
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secreting CAR is now undergoing Phase I clinical testing in patients with epithelial ovarian 
cancer (NCT02498912). Comparably, GD2-redirected CAR T-cells engineered to express a 
constitutively active form of Akt were found to exhibit improved function, survival and 
intrinsic resistance to immunosuppression due to higher sustained levels of NF-κB and anti-
apoptotic genes, such as Bcl-2, Mcl-1 and Bcl-xL [47]. These benefits, however, may be 
offset by the emergence of a more terminally differentiated effector memory phenotype and 
sub-optimal metabolic capacity [75]. Another approach to generate armored CAR T-cells is 
through the co-expression of CD40L. Curran et al. generated a CD19-directed CAR that 
constitutively co-expressed CD40L and which mediated enhanced anti-tumor activity in 
vitro. Enhanced survival benefit was observed when DoHH2 tumor bearing mice were treated 
with CD40L-containing armored CAR T-cells, compared with matched control second 
generation CAR T-cells. This approach alters the tumor microenvironment in a favorable 
manner, thereby enhancing anti-tumor activity [45].   
 
Strategies to enhance CAR T-cell intra-tumoral migration 
Inadequate CAR T-cell trafficking may compromise efficacy, particularly against 
solid tumors. Several strategies have been proposed to address physical and/or molecular 
barriers to CAR T-cell entry. The most straightforward of these entails direct intra-tumoral or 
intra-cavitary CAR T-cell delivery [76]. This approach is supported by evidence that CAR T-
cells largely remain within the tumor after direct delivery [77]. Alternatively, chemokine/ 
chemokine receptor circuits may be harnessed to address this limitation. For example, 
expression of the CXCR3 chemokine receptor may be enhanced by blocking protein kinase A 
localization [34]. Since CAR T-cells are genetically engineered, vectors may alternatively be 
used to co-deliver chemokine receptors that are matched to tumor-specific chemokines [35, 
78]. In a related approach, tumor-tropic oncolytic viruses may be armed with chemokines 
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and/or cytokines and administered prior to CAR T-cell immunotherapy [79]. Penetration of 
CAR T-cells within solid tumors is also recognized to be an important hurdle, particularly 
given the high interstitial pressures that pertain within this environment. To address this, 
CAR T-cells may be engineered to secrete heparanase to disrupt tumor-associated 
extracellular matrix [80]. In addition, tumor cell surface adhesion molecules may be 
upregulated to aid CAR T-cell functionality [81]. 
 
Enhancing CAR metabolism 
The TME is often inhospitable to T-cells due to local hypoxia, low pH, high lactate, 
the absence of critical amino acids such as tryptophan or arginine and the presence of 
immunosuppressive mediators such as kynurenine, prostaglandin E2 and adenosine. Various 
strategies have been proposed to optimize CAR T-cell metabolism in the face of these 
obstacles. One approach entails the overexpression of peroxisome proliferator-activated 
receptor-gamma coactivator 1 alpha (PGC-1α), which leads to enhanced oxidative 
phosphorylation and mitochondrial biogenesis [75]. Since Akt is a negative regulator of 
PGC-1α, inhibition of Akt represents an alternative strategy to achieve this goal. Akt been 
shown to phosphorylate and sequester FOXO in the cytoplasm, thereby inhibiting the 
transcription of FOXO-inducible molecules associated with central memory or stem memory 
phenotype. Pharmacological modulation of this pathway can be achieved using Akt or PI3Kδ 
inhibitors during ex vivo expansion of CAR T-cells, leading to enhanced expression of 
memory markers and superior anti-tumor activity [82]. Similar effects have been reported in 
response to enhanced canonical Wnt/β-catenin signaling, which has been shown to confer a 
stem memory T-cell phenotype [83]. Memory T-cell differentiation may also be favored by 
inhibition of glycolysis (e.g. using the glucose analog 2-deoxyglucose [84]), enforced fatty 
acid oxidation (e.g. by over-expressing carnitine palmitoyltransferase 1a [85]) or by re-
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programming of mitochondrial function to achieve a T-cell metabolic phenotype in which 
catabolic pathways (e.g. oxidative phosphorylation and fatty acid oxidation) dominate over 
anabolic processes (e.g. glycolysis) [86].  
 
Engineering safety in CAR T-cells 
The use of CAR T-cell immunotherapy in the clinic has elicited concerns regarding 
on-target and off-target toxic effects. Particularly severe toxicities include cytokine release 
syndrome (CRS), macrophage activation syndrome (MAS) and neurotoxicity, all of which 
may result in fatal complications [87]. Adoptive cell transfer of 1010 HER2-redirected CAR 
T-cells in a patient with HER2+ metastatic colorectal cancer resulted in fatal multi-organ 
failure due to the binding of low-level antigen on pulmonary epithelium and/ or 
microvasculature [8]. Temporospatial control of CAR T-cells may help to manage these risks 
and can be achieved by engineering on- or off-switches or inducible suicide systems. Herpes 
simplex virus thymidine kinase (HSV-TK)-engineered T-cells are amenable to 
pharmacologic clearance by administration of ganciclovir. This approach has been clinically 
validated in patients undergoing allogeneic hematopoietic stem cell transplantation. However, 
the HSV-TK gene product is highly immunogenic and thus is liable to promote immune-
mediated clearance of engineered cells [88]. Prototypic tetracycline (tet)-on and tet-off 
systems subjugate target gene transcription to the presence or absence of this antibiotic, or 
one of its derivatives. Sakemura et al. have expressed a second generation CD19-specific 
CAR using a third generation tet-on vector, demonstrating loss of CAR expression and 
function in the absence of doxycycline [89]. Alternatively, heterodimerizing agents such as 
AP21967 or gibberellin have been utilized in a split CAR construct, whereby the extracellular 
antigen-binding moiety is linked to an intracellular heterodimerizing module +/- a 
costimulatory domain. Following the delivery of AP21967 or gibberellin, this module 
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heterodimerizes with a second DAP10-linked molecule containing a CD3ζ domain, alone or 
with a further costimulatory domain [37]. Separately, a system compromising a myristoylated 
membrane-tethered chimeric MyD88/CD40 endodomain (GoCART) provides signal 2 for 
optimal CAR function only in the presence of the chemical inducer of dimerization (CID), 
rimiducid [36]. 
The insertion of a suicide gene cassette comprising inducible capase-9 (iCas9) has 
also been utilized to enhance CAR safety. Delivery of CIDs (AP1903 or AP20187) induce 
homodimerization of a chimeric molecule comprising caspase-9 and a drug-binding domain, 
leading to the activation of downstream pro-apoptotic molecules and CAR T-cell death [38]. 
Alternatively, the co-expression of a truncated cell surface molecule such as epidermal 
growth factor receptor or CD20 that is the target of a clinical grade monoclonal antibody 
(such as cetuximab or rituximab) allows for selective elimination of CAR T-cells via 
antibody- and/ or complement-dependent cell-mediated cytotoxicity [30]. Such systems rely 
upon uniform expression of the safety switch following T-cell transduction to avoid CAR T-
cell escape. 
In a distinct approach to restrict CAR T-cell activation to the TME, transcription of 
the CAR-encoding gene has been coupled to a hypoxia-sensitive subdomain of hypoxia-
inducible factor-1 alpha (HIF-1α), leading to enhanced CAR cell surface expression in the 
context of tumor hypoxia [90]. Nonetheless concerns remain about leakiness of gene 
expression using this approach. Likewise, antigen-specific CD8+ T-cells expanded in hypoxic 
conditions prior to adoptive cell transfer have been shown to exhibit greater intrinsic effector 
function due to higher concentrations of granzyme B in their cytolytic granules [91]. 
 
Universal modular CAR designs 
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Various customizable CAR platforms have been designed to reduce the financial and 
human costs associated with the development of individual antigen-targeting CARs. Such 
approaches are particularly welcome in anticipation of the development of “off the shelf” 
allogeneic CAR products. Examples include Fc-specific CARs [92] or orthogonal systems 
whereby a single CAR is designed to target a non-human proteome-derived peptide bound to 
antibody, Fab or scFv targeting modules [50, 93]. Antigen escape may therefore be addressed 
by using multiple exchangeable antibody-bound targeting modules, but the system is reliant 
upon adequate penetration of the TME and sufficient tumor cell surface binding by the 
antibody-conjugated targeting module.  
 
Summary 
Clinical studies have shown impressive results of CAR T-cell therapy and have 
revolutionized the treatment landscape for patients with B-cell malignancies. Further pre-
clinical development and improvements will be crucial to translate these results in other 
malignancies and also address issues that have arisen post-treatment. Modifications of CAR 
scFvs, hinge and costimulatory domains have the potential to address many of the current 
limitations of CARs such as persistence whereas the generation of armored CARs or 
‘TRUCKS’, to achieve the release of cytokines will enhance their expansion and survival. 
Other augmentations that will improve tumor specificity of CAR T-cells include the targeting 
of multiple antigens, which could reduce the chance of antigen escape and also enhance 
safety. Additional engineering of CARs to include suicide genes or iCARs are other possible 
ways to achieve safety and address toxicity, which remains an issue in the clinic. Ultimately, 
pre-clinical research will help to illuminate which strategy or optimization will be best to 
enable the use of CAR T-cells safely and widely.  
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Practice Points  
• CAR T-cell therapies have yielded unprecedented response rates and survival outcomes in 
patients with chemotherapy-resistant and refractory B-cell malignancies.  
• Preclinical evaluation of CD28 versus 4-1BB-containing second generation CD19-directed 
CAR T-cells have revealed differences in cytokine release, effector function and 
persistence. 
• Reducing risk of toxicities such as cytokine-release syndrome and cerebral oedema is 
essential for improving CAR T-cell therapy. 
• Next generation CAR T-cells currently in clinical development have been further 
engineered to enhance polyfunctionality and safety, as such it is likely that CAR T-cell 
therapy will become a standard treatment option for patients in the future. 
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Research Agenda 
• CD19-directed CAR T-cells may fail to induce long-term remissions due to the emergence 
of antigen loss or impaired CAR T-cell persistence. Further research is required to address 
both issues. 
• In addition, the development of safe and effective CAR T-cell therapies for patients with 
non-B-cell malignancies and solid tumors remains compromised by a paucity of targetable 
tumour-associated antigens.  
• Strategies designed to control CAR T-cell functionality spatially, temporally and in a 
modular fashion may also improve safety and efficacy but require clinical evaluation. 
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Figure legends: 
Figure 1: Evolution of first, second, third and fourth generation CARs. First generation 
CARs consist of a scFv typically fused to a CD3ζ activation domain. Second generation 
CARs contain an additional intracellular costimulatory domain, usually CD28 or 4-1BB 
(CD137). Third generation CARs combine two or more costimulatory domains. Fourth 
generation CARs are engineered with an activation inducible element (e.g. NFAT-responsive 
expression cassette) to enable the secretion of a transgenic product such as IL-12. CSD, 
costimulatory domain; ECTM, extracellular targeting moiety; ICD, intracellular domain; 
NFAT, nuclear factor of the activated T-cell; scFv, single chain variable fragment; TMD, 
trans-membrane domain. 
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Figure 2: CAR T-cell engineering for enhanced efficacy & safety. (A) CAR design: 
second and third generation CARs incorporate a variety of costimulatory intracellular 
domains such as CD28, 4-1BB, OX40, ICOS, CD27 or DAP10; these may be further 
engineered to alter the functional characteristics of the CAR T-cells (e.g. mutation of the Lck-
binding site in CD28 may reduce IL-2 production & minimize Treg expansion); the 
extracellular scFv may be substituted with targeting moieties derived from endogenous 
molecules (e.g. the pan-ErbB ligand, T1E [94] or NKG2D [95]), single domain nanobodies or 
monomeric fibronectin-based domains; adjustments to the spacer and/or transmembrane 
domain may also impact upon efficacy. (B) Expression of surface costimulatory molecules: 
examples include chimeric cytokine receptors (e.g. IL-4α/IL-2Rβ), 4-1BBL, CD40L, PD-1-
based costimulatory switch receptors or a membrane tethered chimeric IL-15 fusion 
molecule. (C) Expression of matched chemokine receptors for enhanced intra-tumoral 
trafficking. (D) Constitutive or induced secretion of cytokines, collagenases or molecules 
targeting TME immunosuppression (e.g. anti-PD-1 monoclonal antibodies). (E) Optimizing 
CAR T-cell metabolic capacity and phenotype e.g. by overexpressing PGC-1α, modulating 
the PI3K-Akt or canonical Wnt/β-catenin pathways. (F) Inserting safety systems to address 
toxicity (e.g. HSV-TK, iCas9, truncated EGFR or CD20 targetable with mAbs); engineering 
spatiotemporal control by using chemical inducers of dimerization acting at the level of a 
split CAR or a separate costimulatory module or by regulating gene transcription using the 
synNotch system. (G) Optimizing CAR expression and recycling by utilizing CRISPR/Cas9 
or homing endonucleases to position the CAR within the TRAC locus; utilising self-
inactivating or non-integrative viral vectors, mRNA or transposon/transposase systems. 
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Figure 1: Evolution of first, second, third and fourth generation CARs. First generation CARs consist of a scFv typically fused to a CD3ζ activation 
domain. Second generation CARs contain an additional intracellular costimulatory domain, usually CD28 or 4-1BB (CD137). Third generation CARs combine two 
or more costimulatory domains. Fourth generation CARs are engineered with an activation inducible element (e.g. NFAT-responsive expression cassette) to 
enable the secretion of a transgenic product such as IL-12. CSD, costimulatory domain; ECTM, extracellular targeting moiety; ICD, intracellular domain; NFAT, 
nuclear factor of the activated T-cell; scFv, single chain variable fragment; TMD, trans-membrane domain.
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Figure 2: CAR T-cell engineering for enhanced efficacy & safety. (A) CAR design: second and third generation CARs incorporate a variety of costimulatory intracellular domains such as CD28, 4-1BB, OX40, ICOS, CD27 or 
DAP10; these may be further engineered to alter the functional characteristics of the CAR T-cells (e.g. mutation of the Lck-binding site in CD28 may reduce IL-2 production & minimize Treg expansion); the extracellular scFv 
may be substituted with targeting moieties derived from endogenous molecules (e.g. the pan-ErbB ligand, T1E [90] or NKG2D [91]), single domain nanobodies or monomeric fibronectin-based domains; adjustments to the 
spacer and/or transmembrane domain may also impact upon efficacy. (B) Expression of surface costimulatory molecules: examples include chimeric cytokine receptors (e.g. IL-4α/IL-2Rβ), 4-1BBL, CD40L, PD-1-based 
costimulatory switch receptors or a membrane tethered chimeric IL-15 fusion molecule. (C) Expression of matched chemokine receptors for enhanced intra-tumoral trafficking. (D) Constitutive or induced secretion of cytokines, 
collagenases or molecules targeting TME immunosuppression (e.g. anti-PD-1 monoclonal antibodies). (E) Optimizing CAR T-cell metabolic capacity and phenotype e.g. by overexpressing PGC-1α, modulating the PI3K-Akt or 
canonical Wnt/β-catenin pathways. (F) Inserting safety systems to address toxicity (e.g. HSV-TK, iCas9, truncated EGFR or CD20 targetable with mAbs); engineering spatiotemporal control by using chemical inducers of 
dimerization acting at the level of a split CAR or a separate costimulatory module or by regulating gene transcription using the synNotch system. (G) Optimizing CAR expression and recycling by utilizing CRISPR/Cas9 or homing 
endonucleases to position the CAR within the TRAC locus; utilising self-inactivating or non-integrative viral vectors, mRNA or transposon/transposase systems. 
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